Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China; University of Chinese Academy of Sciences, Beijing, 100049, China.
Hunan Normal University School of Medicine, Changsha, 410081, China.
Antiviral Res. 2020 Oct;182:104884. doi: 10.1016/j.antiviral.2020.104884. Epub 2020 Aug 1.
Japanese encephalitis virus (JEV), a major cause of Japanese encephalitisis, is an arbovirus that belongs to the genus Flavivirus of the family Flaviviridae. Currently, there is no effective drugs available for the treatment of JEV infection. Therefore, it is important to establish efficient antiviral screening system for the development of antiviral drugs. In this study, we constructed a full-length infectious clone of eGFP-JEV reporter virus by inserting the eGFP gene into the capsid-coding region of the viral genome. The reporter virus RNA transfected-BHK-21 cells generated robust eGFP fluorescence signals that were correlated well with viral replication. The reporter virus displayed growth kinetics similar to wild type (WT) virus although replicated a little slower. Using a known JEV inhibitor, NITD008, we demonstrated that the reporter virus could be used to identify inhibitors against JEV. Furthermore, an eGFP-JEV-based high throughput screening (HTS) assay was established in a 96-well format and used for screening of 1443 FDA-approved drugs. Sixteen hit drugs were identified to be active against JEV. Among them, five compounds which are lonafarnib, cetylpyridinium chlorid, cetrimonium bromide, nitroxoline and hexachlorophene, are newly discovered inhibitors of JEV, providing potential new therapies for treatment of JEV infection.
日本脑炎病毒(JEV)是日本脑炎的主要病原体,属于黄病毒科黄病毒属的虫媒病毒。目前,针对 JEV 感染尚无有效的治疗药物。因此,建立高效的抗病毒筛选系统对于开发抗病毒药物至关重要。本研究通过将 eGFP 基因插入病毒基因组的衣壳编码区,构建了全长 eGFP-JEV 报告病毒的感染性克隆。转染报告病毒 RNA 的 BHK-21 细胞产生了强烈的 eGFP 荧光信号,与病毒复制密切相关。报告病毒的生长动力学与野生型(WT)病毒相似,尽管复制速度稍慢。使用已知的 JEV 抑制剂 NITD008,我们证明了报告病毒可用于鉴定针对 JEV 的抑制剂。此外,建立了基于 eGFP-JEV 的高通量筛选(HTS) assay,采用 96 孔格式,筛选了 1443 种已获 FDA 批准的药物。鉴定出 16 种活性药物可有效抑制 JEV。其中,Lonafarnib、十六烷基吡啶氯、十六烷基三甲基溴化铵、硝呋太尔和六氯酚这 5 种化合物是 JEV 的新发现抑制剂,为 JEV 感染的治疗提供了潜在的新疗法。